Safety considerations with the current treatments for peripheral T-cell lymphoma
Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opinion On Drug Safety 2022, 21: 653-660. PMID: 35129014, DOI: 10.1080/14740338.2022.2036120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeripheral T-cell lymphomaT-cell lymphomaCombination chemotherapyTreatment regimensAnthracycline-based combination chemotherapyNK-T cell lymphomaB-cell non-Hodgkin lymphomaSingle-agent chemotherapyAvailable treatment regimensNon-Hodgkin lymphomaT cell subtypesSelection of agentsRelapsed settingAgent chemotherapyNatural killerFrontline treatmentPoor prognosisDisease groupUnique immunobiologyCurrent treatmentCell lymphomaCell disordersSide effectsLymphomaCertain complications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply